

**23-JAN-2018 6:10
OPEN STUDIES IRB REPORT**

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
BREAST	S1207	Brst,Adj,Endocrine+/-Everolimus	03-SEP-13	446	233
	S1416	Brst, TNBC/BRCA, Cis+/- ABT-888	07-JUL-16	263	127
	S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	15-NOV-16	407	185
	A011106	Breast, Neoadj, ALTERNATE study	15-FEB-14	247	117
	A011401	Breast, adj, Stage II/III HER2-, weight loss	29-AUG-16	426	225
	A011502	Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	08-DEC-16	0	209
	A221405	Breast, ET interruption, Pregnancy Outcomes	15-OCT-15	0	56
	B55	Brst, Adj Olaparib for BRCA,TNBC	03-JUL-14	408	180
	E1Z11	Brst,Genetic Predictors of AIMSS	10-MAY-13	227	82
	E2112	Brst,Adv,Exemestane+/-Entinostat	02-JAN-14	296	165
	NRGBR002	Brst, OMBC, II-III, SoC +/- SBRT and/or SA	24-DEC-14	0	5
	NRGBR003	Brst,Adj,TNBC,AC -> WP +/- Carbo	22-JAN-15	436	211
	CCD	S1415CD	TrACER CSF Standing Order Intervention for FN	01-SEP-16	21
S1417CD		Colorectal, Cost Cohort Study	13-MAY-16	211	64
A011104		Preoperative Breast MRI	21-FEB-14	172	56
ERLYTX	S1609	Rare Tumor, Comb Nivo/Ipi	13-JAN-17	348	150
	A071102	GBM, adj TMZ +/- Veliparib	19-SEP-14	373	164
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	06-AUG-15	293	114
	ARST1321	NonRhabdo STS,Pazopanib (PAZNTIS)	16-MAY-14	242	115
	EAY131	MATCH	12-AUG-15	457	231
GI	S1505	Panc,Resect, Perioperative Chemo	12-OCT-15	309	124
	S1613	mCRC, Adv/Met, TP vs CETIRI	09-OCT-17	0	61
	A021501	Adeno Panc,Borderline Resect,Chemo vs ChemoRT	01-DEC-16	0	81
	EA2133	Anal, local recur/met, Cis+5FU vs Taxol/Carbo	29-JAN-16	0	42
	EA2142	GI NEC, Adv G3, EP vs TMZ + CAP	06-NOV-15	197	76
	N1048	Rectal,LocalAdv,ChemoRT+/-FOLFOX	13-JAN-12	0	160
	NRGGI002	Rectal, Ph II, Sensitization using TNT	12-OCT-16	327	133
	R0848	Panc, Adj, Erlotinib v ChemoRT	01-MAR-14	0	146
GU	S1500	pRCC,Adv, Sunitinib vs MET inhib	05-APR-16	217	93
	S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	07-FEB-17	145	65
	S1605	Blad, BCG-Unresponsive NMIBC, Atezolizumab	07-FEB-17	152	70
	A031102	GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	01-JUL-15	59	34

**23-JAN-2018 6:10
OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	EA8141	UTUC, HG, Chemo then Surg	27-JAN-15	152	74
	EA8143	RCC, HR, Surg +/- Nivolumab (PROSPER)	02-FEB-17	0	17
	NRGGU002	Pros, RT + ADT After RP +/- Adj Docetaxel	30-DEC-16	0	103
	R0924	Pros, NADT+WPRT vs. NADT+P&SV RT	07-JUL-11	0	163
LEUK	S1312	ALL, CD22+, REL/REF, Inotuzumab+CVP	01-APR-14	2	3
	S1612	AML/MDS, Age 60+, Aza/Novel Therapeutics	22-DEC-17	0	4
	E1910	BCR-ABL-neg, B ALL, Blinatumomab	23-DEC-13	149	81
	E2906	AML, Age 60+, Clo vs Dauno+Cy	24-FEB-11	144	78
	NHLBIMDS	LEUK, National MDS Study	05-APR-16	253	103
LUNG	S1400	SCCA,Adv, Biomarker Master	15-JUN-14	443	221
	S1400F	Non-Match: MEDI4736 + Tremelimumab	02-OCT-17	0	214
	S1400G	HRRD: Talazoparib (BMN 673)	07-FEB-17	441	220
	S1400I	Non-Match: Nivo + Ipi vs Nivo	18-DEC-15	440	220
	S1403	Adv,EGFR-mt,Afatinib+/-Cetuximab	25-MAR-15	223	94
	S1507	NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	18-JUL-16	208	93
	S1619	Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	03-NOV-17	0	14
	A081105	ALCHEMIST1, EGFR mut, Erlotinib	02-JAN-14	0	247
	A151216	ALCHEMIST0 - screening	06-FEB-14	451	251
	C30610	SCLC, Thoracic RT	21-MAR-08	230	117
	E4512	ALCHEMIST2, ALK mut, Crizotinib	18-AUG-14	467	260
	EA5142	ALCHEMIST3, Non-match, Nivolumab	16-MAY-16	410	235
	NRGCC003	SCLC, PCI or HA-PCI	07-DEC-15	329	142
	R1306	NSCLC,Adv,ALK/EGFR,TargetAgents	04-NOV-13	188	77
LYMPH	S1608	Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	10-AUG-17	0	80
	A051301	ABC DLBCL, Auto HCT and Ibrutinib/Placebo	15-JUL-16	134	63
MELAN	S1320	Adv, BRAF mut, Inter v Contin	22-JUL-14	230	102
	S1512	Melan, Adv, Desmoplastic, MK-3475 (pembro)	20-OCT-16	76	33
	S1607	MELAN, Adv, T-VEC, MK-3475	02-OCT-17	0	10
	S1616	MELAN, Adv, Ipilimumab ± Nivolumab	17-JUL-17	0	60
	EA6134	Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	15-DEC-15	353	147
	EA6141	Melan, Avd, Nivolumab+Ipi ± Sargmostim	01-MAR-16	310	122
MMYEL	E1A11	MM, frontline, BLD vs CLD	22-NOV-13	313	131
OTHER	A091202	Sarc, Efatutazone vs Placebo, Unresect ,Lipo	02-SEP-14	53	30

**23-JAN-2018 6:10
OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	A091304	Adv Sarc, MLN0128 v Pazopanib, PhI/II	26-JAN-15	207	77
	A091305	HN, Adv, Thyroid PPAR agonist + Chemo	01-SEP-14	118	38
	A091401	Sarc,	18-JUN-15	227	85
	A091404	HN, AR+, Enzalutamide	25-SEP-15	92	39
	EA3132	HN SCC, Stg III-IV , Adj RT +/- Cisp	29-MAR-16	0	67
	EAQ152	Communication & education in tumor profiling	26-SEP-16	238	101
	G0263	Cerv, Stg I/IIA, adjv RT vs chemoRT	12-APR-10	0	18
	G0281	Ovar, Recur/prog LG, IC chemo vs trametinib	27-FEB-14	0	84
	NRGBN001	HN, novel vs. std chemoradiation + chemo	28-AUG-15	0	111
	NRGGY004	Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	04-FEB-16	343	162
	NRGGY005	OVAR, Cedir vs Olaparib vs C+O vs Std of Care	06-FEB-16	317	141
	NRGGY011	ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTAT	12-APR-10	0	7
	NRGHN001	Nasopharyngeal , Individual Tx EBV	21-APR-14	192	69
	R0724	Cervical, Chem+RT +/- Adj. Chemo	15-JAN-14	246	100
	R0920	HN, Adv, Postop IMRT ± Cetuximab	24-DEC-13	332	157
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	279	121
PREV	S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac	01-MAR-13	333	117
	A211102	Breast, Atypia via RPFNA, Metformin v Placebo	01-FEB-15	24	9
	A211201	Breast Density, MA.32 companion	22-AUG-12	18	12
	EA1141	Breast, Abbrev. MRI vs Digital Tomosynthesis	02-SEP-16	0	12
SURV	S1316	Compar. Effectiv. Trial for MBO	09-MAR-15	15	22
	S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol	15-SEP-17	0	54
	E1Q11	EROS: Reproductive Health in Cancer Survivors	30-SEP-15	0	51
	EA9131	Leuk, Strategy to decrease early APL deaths	16-AUG-17	0	18
SXQOL	A221101	Glioma, Nuvigil/Placebo Fatigue	03-JUN-13	201	85
	A221102	Brst,Al Arthralgia,Testosterone	07-SEP-12	0	56